DexCom Inc (DXCM) is a leading medical device company that specializes in continuous glucose monitoring (CGM) systems. As a result, it is critical for investors to perform technical analysis on the stock in order to gain insight into its potential future performance. The company's stock price can be analyzed using a variety of technical indicators to evaluate its current and historical trends.

One commonly used technical indicator is the Relative Strength Index (RSI), which measures the speed and change of price movements. A high RSI value indicates that the stock may be overbought, while a low RSI value suggests that the stock may be oversold. By analyzing the RSI of DexCom Inc, investors can determine whether the stock is currently trading at levels that are relatively high or low compared to historical norms.

DexCom  (DXCM) Technical Analysis

Explore the technical analysis indicators for DexCom Inc (DXCM) stock, including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Find insights into the stock's performance and trends without using call to actions.

DexCom Inc (DXCM) Technical Analysis: Stock Indicators, RSI, ADX, MACD, ROC, STOCHRSI, WILLR

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	67.02	Neutral	76.1%
auto_graphMACD	12.69	Neutral	32.4%
auto_graphCCI	130.28	Sell	266.5%
auto_graphADX	34.86	Neutral	-33.9%
auto_graphATR	14.54	Buy	-
auto_graphWILLR	-13.18	Sell	175.4%
auto_graphROC	19.32	Neutral	45.2%
auto_graphSTOCHRSI	100.00	Sell	20.6%

Buy	1	-87.50%
Hold	4	-50.00%
Sell	3	-62.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

DexCom (DXCM) Technical Analysis

Keep an eye on DexCom

Frequently Asked Questions

What are the technical signals for DexCom (DXCM) stock based on the last 30 days?

Take Your Investments to a Whole New Level